...
首页> 外文期刊>Histopathology: Official Journal of the British Division of the International Academy of Pathology >Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath QuPath digital image analysis
【24h】

Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath QuPath digital image analysis

机译:QuationA的验证免疫组织化学染色肿瘤组织微阵列的系统评分

获取原文
获取原文并翻译 | 示例
           

摘要

Aims Output from biomarker studies involving immunohistochemistry applied to tissue microarrays ( TMA ) is limited by the lack of an efficient and reproducible scoring methodology. In this study, we examine the functionality and reproducibility of biomarker scoring using the new, open‐source, digital image analysis software, QuPath . Methods and results Three different reviewers, with varying experience of digital pathology and image analysis, applied an agreed QuPath scoring methodology to CD 3 and p53 immunohistochemically stained TMA s from a colon cancer cohort ( n = 661). Manual assessment was conducted by one reviewer for CD 3. Survival analyses were conducted and intra‐ and interobserver reproducibility assessed. Median raw scores differed significantly between reviewers, but this had little impact on subsequent analyses. Lower CD 3 scores were detected in cases who died from colorectal cancer compared to control cases, and this finding was significant for all three reviewers ( P ‐value range = 0.002–0.02). Higher median p53 scores were generated among cases who died from colorectal cancer compared with controls ( P ‐value range = 0.04–0.12). The ability to dichomotise cases into high versus low expression of CD 3 and p53 showed excellent agreement between all three reviewers (kappa score range = 0.82–0.93). All three reviewers produced dichotomised expression scores that resulted in very similar hazard ratios for colorectal cancer‐specific survival for each biomarker. Results from manual and QuPath methods of CD 3 scoring were comparable, but QuPath scoring revealed stronger prognostic stratification. Conclusions Scoring of immunohistochemically stained tumour TMA s using QuPath is functional and reproducible, even among users of limited experience of digital pathology images, and more accurate than manual scoring.
机译:涉及应用于组织微阵列(TMA)的免疫组织化学的生物标志物研究的旨在受到缺乏有效和可重复的评分方法的限制。在这项研究中,我们研究了使用新的开源,数字图像分析软件,曲线的生物标志物评分的功能和再现性。方法和结果三种不同的审阅者,具有不同的数字病理和图像分析经验,从结肠癌队列(n = 661),将商定的奎纳和P53免疫组织化学染色的TMA S应用于CD 3和P53免疫组织化学染色。手动评估由一名审查员进行CD 3.进行生存分析,并进行了分析和interobserver再现性评估。审阅者之间的中位数原始分数显着差异,但这对随后的分析几乎没有影响。在与对照病例相比,从结肠直肠癌中死亡的病例中检测到降低CD 3分数,并且对于所有三种评论者来说,这种发现都很重要(P-value范围= 0.002-0.02)。与对照相比,从结肠直肠癌中死亡的病例中产生了更高的中位数P53分数(P-value范围= 0.04-0.12)。将偶氮病例与CD 3和P53的低表达的能力表现出所有三种评论者之间的良好协议(Kappa得分范围= 0.82-0.93)。所有三种审查员都产生了二分表达分数,导致每种生物标志物的结肠直肠癌特异性存活率非常相似的危险比。 CD 3评分的手动和Qupath方法的结果相当,但曲线评分显示出更强的预后分层。结论使用曲线的免疫组织化学染色肿瘤TMAS的评分是功能性和可重复的,即使是数字病理图像的有限经验的用户,比手动评分更准确。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号